Gland Pharma Secures USFDA Approval for Angiotensin II Acetate Injection with 180-Day Market Exclusivity

Gland Pharma has received approval from the U.S. Food and Drug Administration (USFDA) for its Angiotensin II Acetate injection, granting the company a 180-day exclusivity period for the product. The approval marks a significant milestone for Gland Pharma, allowing it to exclusively market the medication in the United States for six months.

The Angiotensin II Acetate injection is used in medical settings to treat conditions such as septic or distributive shock by increasing blood pressure in adults who are critically ill. The USFDA’s decision enables Gland Pharma to introduce this treatment option into the U.S. market under exclusive rights, providing healthcare providers with an additional resource for managing these life-threatening conditions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 4, 2025

Related posts:

Generic Drug Stability: 5 Key Factors Critical for Manufacturers, According to DrugPatentWatch QA Ensures Generic Drugs Mirror Branded Quality Through Every Development Stage, DrugPatentWatch Reports Securing Drug Combination Patents Requires Focus on Component Interaction. Health Secretary Robert F. Kennedy Jr. Takes Steps That May Alter Vaccine Policies for Pregnant Women and Children

Author

Mark Chiang